AVIPure® affinity resins address the market need for high performance and caustic stability WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins – AVIPure® - AAV9, AVIPure® - AAV8, and AVIPure® - AAV2 – were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors used today. AAV vectors are the leading platform for gene delivery for the treatment of a variety of human diseases.
Read More
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addition to performance-based earnout payments over the next three years. Avitide is a leading chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines.
Read More
Avitide Inc., the industry leader in the discovery and development of custom affinity purification resins, announce a partnership expansion with Allergan. Under the terms of the agreement, Avitide will use its proprietary affinity chromatography discovery, development, and supply platform for programs defined by Allergan.
Read More
Avitide, Inc., the industry leader in the discovery and development of custom affinity purification resins, announces that it has entered into an exclusive license agreement to support the development of one of Gemini Therapeutics’ therapeutic programs.
Read More 